Insulet Omnipod 5 Receives FDA Clearance for Enhanced Algorithm Features

Insulet Corporation has received FDA clearance for enhancements to the Omnipod 5 Automated Insulin Delivery System. The updates include a lower 100 mg/dL Target Glucose option and a more seamless automated experience. The new features address the two most requested enhancements and reflect the company's commitment to delivering meaningful innovation for those living with diabetes. The enhancements are designed to strengthen clinical outcomes while making the Pod experience simpler, more personalized, and seamless. The updates are anticipated to launch in the US in the first half of 2026.